Synonyms and keywords: Blalock Taussig Procedure, Procedure, Blalock-Taussig, Subclavian Pulmonary Artery Shunt, Blue Baby Operations, Modified Blalock-Taussig Procedure
Overview
The Blalock-Taussig shunt is a palliativesurgical procedure done for cyanotic heart defects. This procedure is used to deviate blood flow to lungs from the systemic circulation to relieve cyanosis while a definitive corrective surgery can be performed at a later time. Connection between subclavian artery and pulmonary artery is usually made. Usually, two types of shunts are used i.e classic or original Blalock-Taussig shunt and modified Blalock Taussig shunt. The classic/original BT shunt has been modified into modified Blalock-Taussig Shunt (mBTS). In this modified procedure, a graft from innominate artery or subclavian artery is placed to the corresponding pulmonary artery. This type of BT shunt has superior prognostic value over the classical shunt leading to a greater rate of shunt patency in 3-5 years as compared to the classic or original BT Shunt.
Historical Perspective
Classic or Original Shunt
The classic or original BT shunt procedure was named after a surgeon in Baltimore, Alfred Blalock (1899–1964), and a cardiologist in Baltimore/Boston, Helen B. Taussig (1898–1986), who along with Blalock's African American laboratory technician Vivien Thomas (1910–1985), developed and described the procedure.
In 1943, Dr. Taussig approached Blalock and Thomas in their Hopkins laboratory to work on this shunt as it was hypothesized that a shunt mimicking PDA can relieve the cyanosis and improve oxygenation in congential cyanotic diseases.[1]
It is the most immediate risk during the post-operative period. It can lead to drop in oxygen saturation secondary due to shunt thrombosis or kinking. Shunt failure is a surgical emergency and should be managed as follows:
Anticoagulation should be started. Heparin should be instituted promptly. It should be again administered if there is less risk of bleeding usually after 4 hours post-op ( when the drainage of the chest shows <3ml/kg/h and aPTT is <60s. Heparin induced thrombocytopenia can occur and should be managed accordingly.
Patient is put on aspirin which is usually started at 3-5 mg/kg (max. dose 75mg ) OD.
Heparin should be continued until there is a second dose of aspirin.
Blockage of BT shunt
Blockage or shunt thrombosis is another surgical emergency.
Operative management is usually required and the shunt is usually repaired or replaced if necessary.
High pulmonary blood flow
The appropriate size of BT shunt is very important to prevent the long term complications regarding high pulmonary blood flow or high oxygen saturation.
Refractory to medical management cases are usually treated with a surgical approach that involves pulmonary artery band or clamping.
Prognosis
Modified Blalock-Taussig Shunt has a superior prognostic value over classic Blalock-Taussig Shunts. Following prognostic factors are compared between the two procedures in multiple studies:[7][8][9][10][11][12]
The increase in saturation of oxygen is greater in the modified shunt as compared to the classic shunt.
Modified shunt has an 88.8% patency rate in 3-5 years. Whereas for the classic shunt, the patency rate is 90% in the first year, 62% in two years, and 78.0% in 3 years.
The risk of early shunt failure is 20.8% in modified and 51.7% in the classic shunt.
Post-shunt increase in pulmonary arterial index (mm2/m2) is 158 +/- 21 versus 117 +/- 52 in classic Blalock-Taussig shunt.
Internal mammary artery is used for this purpose and to create a systemic to pulmonary conduit after there has been a failure of previously used BT shunt.
It leads to adaptation of growth and flow and reduces the risk for graft infection.
↑Eghtesady, Pirooz (2015). "Potts Shunt for Children With Severe Pulmonary Hypertension". Operative Techniques in Thoracic and Cardiovascular Surgery. Elsevier BV. 20 (3): 293–305. doi:10.1053/j.optechstcvs.2016.02.003. ISSN1522-2942.
↑TRUCCONE, NESTOR J.; BOWMAN, FREDERICK O.; MALM, JAMES R.; GERSONY, WELTON M. (1974). "Systemic-Pulmonary Arterial Shunts in the First Year of Life". Circulation. Ovid Technologies (Wolters Kluwer Health). 49 (3): 508–511. doi:10.1161/01.cir.49.3.508. ISSN0009-7322.